Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$47.94 USD
+1.80 (3.90%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $47.91 -0.03 (-0.06%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RVMD 47.94 +1.80(3.90%)
Will RVMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RVMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RVMD
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
RVMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates
Other News for RVMD
Revolution Medicines price target raised by $2 at Barclays, here's why
Barclays Remains a Buy on Revolution Medicines (RVMD)
Revolution Medicines price target raised by $10 at Oppenheimer, here's why
Revolution Medicines price target raised by $12 at H.C. Wainwright, here's why
Revolution Medicines price target raised by $7 at BofA, here's why